The evolution of the European risk stratification system for pulmonary arterial hypertension
- PMID: 39237314
- DOI: 10.1183/13993003.00943-2024
The evolution of the European risk stratification system for pulmonary arterial hypertension
Conflict of interest statement
Conflict of interest: S. Sahay has been a consultant and advisor to Janssen, United Therapeutics, MERCK, Keros, Gossamer Bio and Liquidia, and participated on a data safety monitoring board for NIH grants. R.L. Benza reports consulting fees from Cereno, Gossamer Bio, United Therapeutics, Abbott, InsMED and Respira.
Comment on
-
Risk stratification refinements with inclusion of haemodynamic variables at follow-up in patients with pulmonary arterial hypertension.Eur Respir J. 2024 Sep 5;64(3):2400197. doi: 10.1183/13993003.00197-2024. Print 2024 Sep. Eur Respir J. 2024. PMID: 38663975 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources